Table 4.

Treatment-emergent adverse events in US phase 2 trial patients

Relationship to PRL3-zumab	Unrelateda				Possibly relateda				Relateda
	1	2	3	≥4	1	2	3	≥4	1	2	3	≥4
Any TEAEb	127	105	55	3	25	13	0	0	14	6	0	0
Any serious TEAE	0	2	36	5	0	0	0	0	0	0	0	0
Action taken because of TEAE
Dose interruption	0	0	3	1	0	0	0	0	0	0	0	0
Dose reduction	0	0	0	0	0	0	0	0	0	0	0	0
Treatment discontinuation	0	0	0	0	0	0	0	0	0	0	0	0
TEAE in each system
Nervous system disorders	9	2	2	0	1	0	0	0	1	1	0	0
Respiratory, thoracic, and mediastinal disorders	7	11	2	1	1	0	0	0	3	1	0	0
Cardiac disorders	3	2	1	0	1	0	0	0	0	0	0	0
Psychiatric disorders	4	1	0	0	0	2	0	0	0	0	0	0
Gastrointestinal disorders	19	22	14	0	10	1	0	0	4	0	0	0
Hepatobiliary disorders	0	2	6	0	0	0	0	0	0	0	0	0
Musculoskeletal/connective tissue disorders	13	10	3	0	0	0	0	0	1	1	0	0
Renal and urinary disorders	2	3	0	2	0	0	0	0	1	0	0	0
Eye disorders	5	1	0	0	0	0	0	0	0	0	0	0
Reproductive system and breast disorders	2	3	0	0	0	0	0	0	0	0	0	0
General/administration site disorders	15	9	3	0	7	4	0	0	0	1	0	0
Skin and subcutaneous tissue disorders	4	1	0	0	1	1	0	0	1	0	0	0
Blood and lymphatic system disorders	5	5	9	0	0	0	0	0	0	0	0	0
Vascular disorders	1	1	1	0	0	0	0	0	0	1	0	0
Neoplasms benign, malignant, and unspecified	3	0	2	0	0	0	0	0	0	0	0	0
Metabolism and nutrition disorders	17	20	2	0	1	3	0	0	2	0	0	0
Infections and infestations	2	5	3	0	0	0	0	0	0	0	0	0
Investigations	13	5	6	0	3	2	0	0	0	1	0	0
Injury, poisoning, and procedural complications	2	1	1	0	0	0	0	0	1	0	0	0
Ear and labyrinth disorders	1	0	0	0	0	0	0	0	0	0	0	0
Endocrine disorders	0	1	0	0	0	0	0	0	0	0	0	0

^a“Unrelated, possibly related, related” indicate relationship to study drug.

^bTEAE, treatment-emergent adverse event.